Andrew Slavitt Net Worth

The estimated Net Worth of Andrew M Slavitt is at least $17.6 Million dollars as of 12 May 2023. Mr. Slavitt owns over 95,109 units of Exact Sciences stock worth over $16,799,184 and over the last 5 years he sold EXAS stock worth over $0. In addition, he makes $780,000 as Director at Exact Sciences.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Slavitt EXAS stock SEC Form 4 insiders trading

Andrew has made over 1 trades of the Exact Sciences stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 95,109 units of EXAS stock worth $6,098,389 on 12 May 2023.

The largest trade he's ever made was exercising 95,109 units of Exact Sciences stock on 12 May 2023 worth over $6,098,389. On average, Andrew trades about 19,022 units every 0 days since 2019. As of 12 May 2023 he still owns at least 261,996 units of Exact Sciences stock.

You can see the complete history of Mr. Slavitt stock trades at the bottom of the page.

Andrew Slavitt biography

Andrew M. Slavitt serves as Director of the Company. He is the founder and General Partner of Town Hall Ventures, which invests in healthcare innovations in vulnerable communities, a position he has held since 2018. Prior to that he served as the Acting Administrator for the Centers for Medicare & Medicaid Services, from 2015 to 2017, and as Group Executive Vice President of Optum, UnitedHealth Group’s health services platform, from 2012 to 2014. From 2006 through 2011, Mr. Slavitt was the CEO of OptumInsight (formerly Ingenix), a UnitedHealth Group subsidiary. He serves on the Board of Directors of United States of Care, a national non-profit health think-tank and advocacy organization, is co-chair of the Future of Healthcare Initiative at the Bipartisan Policy Center, and previously served as a director of Capella Eduction Company, an eduction services company (formerly Nasdaq: CPLA). Mr. Slavitt received his MBA from Harvard Business School and bachelor of arts and bachelor of science degrees from the University of Pennsylvania.

What is the salary of Andrew Slavitt?

As the Director of Exact Sciences, the total compensation of Andrew Slavitt at Exact Sciences is $780,000. There are 14 executives at Exact Sciences getting paid more, with Kevin Conroy having the highest compensation of $18,716,500.

How old is Andrew Slavitt?

Andrew Slavitt is 54, he's been the Director of Exact Sciences since 2019. There are 13 older and 9 younger executives at Exact Sciences. The oldest executive at Exact Sciences Corp. is James Doyle, 74, who is the Independent Director.

What's Andrew Slavitt's mailing address?

Andrew's mailing address filed with the SEC is C/O BRIGHT HEALTH GROUP, INC., 8000 NORMAN CENTER DRIVE, SUITE 900, MINNEAPOLIS, MN, 55437.

Insiders trading at Exact Sciences

Over the last 21 years, insiders at Exact Sciences have traded over $118,141,352 worth of Exact Sciences stock and bought 191,930 units worth $1,451,887 . The most active insiders traders include Kevin T Conroy, Edwin M Jr Kania, and Maneesh Arora. On average, Exact Sciences executives and independent directors trade stock every 12 days with the average trade being worth of $1,667,056. The most recent stock trade was executed by Brian Baranick on 5 August 2024, trading 2,712 units of EXAS stock currently worth $173,893.

What does Exact Sciences do?

exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences'​ noninvasive colon cancer screening test, visit cologuardtest.com

Complete history of Mr. Slavitt stock trades at Exact Sciences and Bright Health

Exact Sciences executives and stock owners

Exact Sciences executives and other stock owners filed with the SEC include:

• Kevin Conroy,
  Chairman of the Board, President, Chief Executive Officer
• Mark Stenhouse,
  General Manager - Screening
• Jeffrey Elliott,
  Chief Financial Officer
• D. Scott Coward,
  Senior Vice President, Chief Administrative Officer, General Counsel, Secretary
• Jake Orville,
  General Manager - Pipeline
• Ana Hooker,
  Senior Vice President, Operations
• Graham Lidgard,
  Senior Vice President, Chief Scientific Officer
• Kevin T. Conroy,
  Chairman, Pres & CEO
• G. Bradley Cole,
  Gen. Mang. of Precision Oncology
• Mark Stenhouse,
  Advisor
• Graham P. Lidgard,
  Emeritus Chief Science Officer
• Jeffrey T. Elliott CFA,
  Exec. VP, CFO & COO
• D. Scott Coward,
  Chief Admin. Officer, Exec. VP, Gen. Counsel & Sec.
• Kathleen Sebelius,
  Independent Director
• Andrew Slavitt,
  Director
• Pierre Jacquet,
  Independent Director
• Jake Orville,
  Gen. Mang. of Pipeline
• Ana Hooker,
  Sr. VP of Operations
• James Doyle,
  Independent Director
• Michael Wyzga,
  Independent Director
• Daniel Levangie,
  Independent Director
• Katherine Zanotti,
  Independent Director
• Thomas Carey,
  Independent Director
• Shacey Petrovic,
  Director
• Gisela Paulsen,
  General Manager - Precision Oncology
• Torsten Hoof,
  General Manager - International
• Freda Lewis-Hall,
  Independent Director
• Scott Johnson,
  Senior Vice President, Research and Development
• Vic Parker,
  Head of Sales
• Tim Caprez,
  Chief Compliance Counsel & VP
• Megan Jones,
  Associate Mang. of Investor Relations
• Dr. Scott C. Johnson Ph.D.,
  Chief Science Officer and Sr. VP of R&D
• Gary Frings,
  Chief Information Officer
• Lionel Sterling,
  Director
• John A. Fallon,
  Director
• David Thompson,
  Director
• G Bradley Cole,
  General Manager - Diagnostics
• Paul J Clancy,
  
• Michael J Barber,
  
• Eli Casdin,
  Director
• Anthony P Shuber,
  Executive Vice President
• John A Jr Mccarthy,
  Chief Financial Officer
• Don M Hardison,
  President, CEO and Director
• Barry M Berger,
  SVP, Chief Medical Officer
• William J. Megan,
  SVP, Finance & PFO
• John K Bakewell,
  Chief Financial Officer
• Jeffrey R Luber,
  General Counsel
• Edwin M Jr Kania,
  Director
• Charles R Jr Carelli,
  Prin. Acct. Off. & Corp. Ctlr.
• Patrick J Zenner,
  Director
• Stanley N Lapidus,
  Director
• John M Krayacich,
  SVP, Sales and Marketing
• Richard W Barker,
  Director
• Laura S Stoltenberg,
  Chief Commercial Officer
• Cornelius Iii Mcgillicudy,
  Director
• Harry W Wilcox,
  Senior Vice President and CFO
• Lance Willsey,
  Director
• Michael E Singer,
  Director
• Maneesh Arora,
  Vice President
• James P Connelly,
  Director
• Sally Crawford,
  Director
• Sarah Condella,
  EVP, Human Resources
• Timothy J Scannell,
  Director
• James Herriott,
  SVP, General Counsel & Sec
• Everett Cunningham,
  Chief Commercial Officer
• Jacob A Orville,
  EVP, GM, Screening
• Brian Baranick,
  EVP, GM, Precision Oncology